← Leaderboards
Martin Kampmann
University Of California, San Francisco
$17,201,095
Attributed
$40,360,925
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.6M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,723,239 · 12
By mechanism
U01$28,266,767 · 2
U54$10,391,816 · 2
R01$7,085,251 · 4
DP2$2,324,850 · 1
R56$768,883 · 1
R00$747,000 · 1
Top collaborators
- Sally Temple9 shared
- Daniel H Geschwind8 shared
- Alison M Goate8 shared
- Oscar Harari8 shared
- Celeste Marie Karch8 shared
- Kevin M Pumiglia8 shared
- Kristen Leanne Zuloaga8 shared
- Nevan J Krogan7 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- John D Gross$17,630,943
- Susan Halabi$7,630,539
- Julie Siegenthaler$5,647,396
- Armin Reza Afshar$1,130,602
- Yifan Cheng$24,875,519
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCellsGenesPathway InteractionsNeuronsInduced Pluripotent Stem CellCrispr InterferenceBrainPhenotypeComplexGeneticMolecularIn VivoBaseMapsTau ProteinsTechnologyLinkProteinsGene ExpressionGenomicsBiologicalNerve DegenerationPathologic
Grant awards (45)
Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau Haplotype on Neurodegeneration Risk in FTD and PSP$1,827,905
U54 · FY2025 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,514,673
U01 · FY2025 · AG
Aberrant proteomes in tauopathy: revealing functional consequences via multimodal proteomics$816,661
R01 · FY2025 · AG
Impact of m6A RNA modifications in Alzheimer's disease and tauopathies$805,573
R01 · FY2025 · AG · contact PI
Molecular mechanisms of selective vulnerability of neurons to tauopathy$729,556
R01 · FY2025 · AG · contact PI
Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau Haplotype on Neurodegeneration Risk in FTD and PSP$83,873
U54 · FY2025 · NS
Uncovering the genetic mechanisms of the Chromosome 17q21.31 Tau haplotype on neurodegeneration risk in FTD and PSP$1,834,302
U54 · FY2024 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,573,956
U01 · FY2024 · AG
Molecular mechanisms of selective vulnerability of neurons to tauopathy$744,445
R01 · FY2024 · AG · contact PI
Identification of AD-risk genes affecting endolysosomal and lipid homeostasis pathways$422,406
U01 · FY2024 · AG
Uncovering the genetic mechanisms of the Chromosome 17q21.31 Tau haplotype on neurodegeneration risk in FTD and PSP$1,827,156
U54 · FY2023 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,603,401
U01 · FY2023 · AG
Molecular mechanisms of selective vulnerability of neurons to tauopathy$744,445
R01 · FY2023 · AG · contact PI
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$93,149
U01 · FY2023 · AG
Uncovering the genetic mechanisms of the Chromosome 17q21.31 Tau haplotype on neurodegeneration risk in FTD and PSP$37,683
U54 · FY2023 · NS
Uncovering the Genetic Mechanisms of the Chromosome 17q21.31 Tau Haplotype on Neurodegeneration Risk in FTD and PSP$23,687
U54 · FY2023 · NS
The Psychiatric Cell Map Initiative: Connecting Genomics, Subcellular Networks, and Higher Order Phenotypes$3,701,790
U01 · FY2022 · MH
Uncovering the genetic mechanisms of the Chromosome 17q21.31 Tau haplotype on neurodegeneration risk in FTD and PSP$1,834,889
U54 · FY2022 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,635,911
U01 · FY2022 · AG
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics$646,266
R01 · FY2022 · AG · contact PI
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$121,788
U01 · FY2022 · AG
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$31,078
U01 · FY2022 · AG
The Psychiatric Cell Map Initiative: Connecting Genomics, Subcellular Networks, and Higher Order Phenotypes$4,247,206
U01 · FY2021 · MH
Uncovering the genetic mechanisms of the Chromosome 17q21.31 Tau haplotype on neurodegeneration risk in FTD and PSP$1,892,819
U54 · FY2021 · NS
Investigating the Functional Impact of AD Risk Genes on Neuro-Vascular Interactions$1,658,307
U01 · FY2021 · AG
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics$646,266
R01 · FY2021 · AG · contact PI
Spatiotemporal and functional convergence of genes implicated in ASD$137,275
U01 · FY2021 · MH
The Psychiatric Cell Map Initiative: Connecting Genomics, Subcellular Networks, and Higher Order Phenotypes$3,628,784
U01 · FY2020 · MH
Proteomics Integration and Expansion of Downstream Analysis Capabilities into the CReD Portal$649,398
U01 · FY2020 · MH
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics$646,006
R01 · FY2020 · AG · contact PI
Core D: CRISPRi/a Core$180,271
U54 · FY2020 · NS · contact PI
The Psychiatric Cell Map Initiative: Connecting Genomics, Subcellular Networks, and Higher Order Phenotypes$3,605,729
U01 · FY2019 · MH
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics$642,817
R01 · FY2019 · AG · contact PI
Core D: CRISPRi/a Core$181,010
U54 · FY2019 · NS · contact PI
The Psychiatric Cell Map Initiative: Connecting Genomics, Subcellular Networks, and Higher Order Phenotypes$3,641,916
U01 · FY2018 · MH
Uncovering mechanisms of selective vulnerability by CRISPR-based genetic screens$768,883
R56 · FY2018 · AG · contact PI
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics$663,216
R01 · FY2018 · AG · contact PI
Core D: CRISPRi/a Core$184,501
U54 · FY2018 · NS · contact PI
Stress response networks in cancer: systematic mapping and therapeutic potential$249,000
R00 · FY2017 · CA · contact PI
Core D: CRISPRi/a Core$242,581
U54 · FY2017 · NS · contact PI
Stress response networks in cancer: systematic mapping and therapeutic potential$249,000
R00 · FY2016 · CA · contact PI
Core D: CRISPRi/a Core$241,139
U54 · FY2016 · NS · contact PI
Rewiring of the human protein homeostasis network in normal and disease contexts$2,324,850
DP2 · FY2015 · GM · contact PI
Stress response networks in cancer: systematic mapping and therapeutic potential$249,000
R00 · FY2015 · CA · contact PI
Stress response networks in cancer: systematic mapping and therapeutic potential$138,672
K99 · FY2014 · CA · contact PI